Status:

UNKNOWN

SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

Lead Sponsor:

First Affiliated Hospital of Zhejiang University

Conditions:

Unresectable Hepatocellular Carcinoma

Portal Vein Thrombosis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.

Detailed Description

HCC Patients classified as BCLC stage C present with PVTT, and the recommended first-line treatment is systemic therapy with sorafenib according to updated Barcelona Clinical Liver cancer (BCLC) treat...

Eligibility Criteria

Inclusion

  • Age \>18 years
  • Child-Pugh score ≤ 7
  • Performance status: ECOG score ≤ 2
  • HCC diagnosed by biopsy or by the noninvasive criteria of the Chinese Liver Cancer Guideline 2017
  • the primary HCC being unresectable (BCLC C stage/ CNLC Ⅲa-b) according to NCCN guideline
  • No previous therapy for HCC
  • at least one measurable target lesion according to RECIST 1.1
  • Adequate hematopoietic function: Hemoglobin ≥ 8.5 g/dL; Absolute neutrophil count ≥ 750/mm3; Platelet count ≥ 50,000/mm3
  • Serum total bilirubin ≤ 2 x ULN
  • Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 10 x ULN
  • Creatinine ≤ 1.5 x ULN
  • No plan for pregnancy or breast feeding. Active contraception.
  • Willing to give informed consent

Exclusion

  • Prior history to or exposure of transarterial chemoembolization, external beam radiation to liver, or sorafenib
  • Complete obstruction of hepatic outflow
  • Uncontrolled ascites of hepatic encephalopathy
  • Prior liver transplantation
  • Positive for human immunodeficiency virus (HIV)
  • Active gastric or duodenal ulcer
  • Other uncontrolled comorbidities or malignancy
  • Inability to give informed consent

Key Trial Info

Start Date :

April 30 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2023

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT04387695

Start Date

April 30 2020

End Date

August 1 2023

Last Update

February 16 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, China, 310003

SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | DecenTrialz